当前位置: X-MOL 学术ACS Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Estrogen Receptor Degrading PROTACS for the Treatment of Breast Cancer
ACS Medicinal Chemistry Letters ( IF 3.5 ) Pub Date : 2020-11-18 , DOI: 10.1021/acsmedchemlett.0c00589
Robert B Kargbo 1
Affiliation  

This paper was originally published ASAP on November 18, 2020. There was a missing double bond in the indole core in the structures. The corrected version was reposted on November 20, 2020. Pagano, M. T.; Ortona, E.; Dupius, M. L. Front. Endocrinol. 2020, 11, 506. Chong, Q.; Kok, Z.; Bui, N.; Pharmacol. Res. 2020, 156, 104686. Pedroza, D. A.; Subramani, R.; Lakshmanaswamy, R. Cancers 2020, 12, 2440. Ma, G.; Zhang, B.; Xu, J. Breast Cancer Res. Treat. 2020, 180, 831. Liu, Y.; Ma, H.; Yao, J. OncoTargets Ther. 2020, 13, 2183. The author declares no competing financial interest. The author declares no competing financial interest. This article has not yet been cited by other publications.

中文翻译:

用于治疗乳腺癌的雌激素受体降解 PROTACS

该论文最初于 2020 年 11 月 18 日尽快发表。结构中的吲哚核中缺少一个双键。更正后的版本已于 2020 年 11 月 20 日重新发布。帕加诺, MT ; 奥尔托纳,E杜皮乌斯,ML 正面。内分泌。 2020 11,506。冲,Q科克,Z裴,N.; 药学。水库 2020156,104686。佩德罗萨,DA苏布拉马尼,R拉克什马纳斯瓦米,R. 癌症 2020 , 12 , 2440。马,G张,B徐,J. 乳腺癌研究。对待。 2020 180,831。刘,Y马,H姚,J. OncoTargets Ther。 2020 13,2183作者宣称没有竞争经济利益。作者声明没有竞争性经济利益。这篇文章还没有被其他出版物引用。
更新日期:2020-12-10
down
wechat
bug